Zobrazeno 1 - 10
of 1 446
pro vyhledávání: '"T-cell acute lymphoblastic leukemia"'
Publikováno v:
Zhongliu Fangzhi Yanjiu, Vol 51, Iss 8, Pp 648-654 (2024)
Tumor immunotherapy occupies a pivotal position in the field of hematological malignancies. Chimeric antigen receptor (CAR) T-cell therapy has established a new therapeutic pattern for hematological immunotherapy and achieved satisfactory clinical re
Externí odkaz:
https://doaj.org/article/356ab3a80d3b45df983e66a0bbd94215
Autor:
Shiqi Li, Zhongtao Yuan, Lin Liu, Yu Li, Le Luo, Lihui Peng, Mengli Xu, Ping Yin, Yingnian Chen, Xiaoping Li, Qingying Zang, Xi Zhang, Sanbin Wang
Publikováno v:
eJHaem, Vol 5, Iss 3, Pp 584-588 (2024)
Abstract CD7 targeted CAR‐T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo‐HSCT. Here we reported a special case that a boy diagnosed with r
Externí odkaz:
https://doaj.org/article/65d1117ca02440e58d921b557c836e0c
Autor:
Lian-Lian Li, Yue-Ping Xia, Qianqian Li, Peng Wang, Ping-Ping Sun, Xing-Guang Wang, Rui Zhang
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionChimeric antigen receptor T-cell (CAR-T) therapy has emerged as a promising approach for treating relapsed/refractory (r/r) T-cell acute lymphoblastic leukemia (T-ALL). However, it is mostly used as a bridging therapy for allogeneic hemat
Externí odkaz:
https://doaj.org/article/edeebdde399e42b3ba76dec48f22783c
Publikováno v:
Frontiers in Hematology, Vol 3 (2024)
Early precursor T-cell acute lymphoblastic leukemia (ETP-ALL) is a rare type of T-cell ALL (T-ALL) that was initially described in 2009. Since its initial description, it has been formally recognized as a distinct entity, according to the 2016 World
Externí odkaz:
https://doaj.org/article/7bbae3fec53e4da89b44e840a40ecc4e
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e37313- (2024)
Objective: Due to the high drug resistance and relapse rate of T-cell acute lymphoblastic leukemia (T-ALL), the prognosis is usually poor. Therefore, there is an urgent need to find safer and more effective therapeutic drugs. Huaier and its preparati
Externí odkaz:
https://doaj.org/article/98c3e4d980624eb38a4c4073a9944c3d
Publikováno v:
Genes and Diseases, Vol 11, Iss 5, Pp 100949- (2024)
T-cell acute lymphoblastic leukemia (T-ALL), a heterogeneous hematological malignancy, is caused by the developmental arrest of normal T-cell progenitors. The development of targeted therapeutic regimens is impeded by poor knowledge of the stage-spec
Externí odkaz:
https://doaj.org/article/57c1b3b107c441b19a1f2f98c13f9770
Autor:
Yuichi Nagamatsu, Takeshi Isoda, Motoki Inaji, Jun Oyama, Daiki Niizato, Dan Tomomasa, Noriko Mitsuiki, Motoi Yamashita, Takahiro Kamiya, Kohsuke Imai, Hirokazu Kanegane, Tomohiro Morio, Masatoshi Takagi
Publikováno v:
BMC Pediatrics, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background T-cell acute lymphoblastic leukemia (T-ALL) tends to involve central nervous system (CNS) infiltration at diagnosis. However, cases of residual CNS lesions detected at the end of induction and post early intensification have not b
Externí odkaz:
https://doaj.org/article/1da89f19684f4ebb99bfdf743c2defd1
Autor:
Minu Singh, Pankaj Sharma, Prateek Bhatia, Amita Trehan, Rozy Thakur, Sreejesh Sreedharanunni
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-9 (2024)
Abstract Introduction T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease with poor prognosis and inferior outcome. Although multiple studies have been perform on genomics of T-ALL, data from Indian sub-continent is sca
Externí odkaz:
https://doaj.org/article/d610686b1dc04a3ba53460c3e4705f7a
Autor:
Hisashi Ishida, Toshihiko Imamura, Ryoji Kobayashi, Yoshiko Hashii, Takao Deguchi, Takako Miyamura, Megumi Oda, Masaki Yamamoto, Keiko Okada, Hideki Sano, Katsuyoshi Koh, Yuki Yuza, Kenichiro Watanabe, Noriyuki Nishimura, Tetsuya Takimoto, Akiko Moriya‐Saito, Masahiro Sekimizu, Souichi Suenobu, Shosuke Sunami, Keizo Horibe
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Asparaginase is essential for treating T‐cell acute lymphoblastic leukemia (T‐ALL). Despite the ongoing debate on whether T‐ALL and T‐cell lymphoblastic lymphoma (T‐LBL) are the same disease entity or two distinct diseas
Externí odkaz:
https://doaj.org/article/281b826416d845c9b4a6119f4b9e9d3b
Autor:
Marie Emilie Dourthe, André Baruchel
Publikováno v:
EJC Paediatric Oncology, Vol 3, Iss , Pp 100150- (2024)
T-cell acute lymphoblastic leukemia (T-ALL) has a dismal prognosis in case of relapsed or refractory disease. Contrary to B-ALL, few immunotherapies are available for T-ALL. Use of autologous CAR T-cells is challenging due to shared antigen between l
Externí odkaz:
https://doaj.org/article/5b005f7d9abb41a5aece2aecd397ebf6